184 related articles for article (PubMed ID: 33391451)
1. Minimal Residual Disease and Survival Outcomes in Patients with Mantle Cell Lymphoma: a systematic review and meta-analysis.
Zhou Y; Chen H; Tao Y; Zhong Q; Shi Y
J Cancer; 2021; 12(2):553-561. PubMed ID: 33391451
[No Abstract] [Full Text] [Related]
2. Association of minimal residual disease levels with clinical outcomes in patients with mantle cell lymphoma: A meta-analysis.
Wu X; Lu H; Pang T; Li X; Luo H; Tan H; Liu S
Leuk Res; 2021 Sep; 108():106605. PubMed ID: 34090063
[TBL] [Abstract][Full Text] [Related]
3. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.
Munshi NC; Avet-Loiseau H; Rawstron AC; Owen RG; Child JA; Thakurta A; Sherrington P; Samur MK; Georgieva A; Anderson KC; Gregory WM
JAMA Oncol; 2017 Jan; 3(1):28-35. PubMed ID: 27632282
[TBL] [Abstract][Full Text] [Related]
4. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
Kolstad A; Pedersen LB; Eskelund CW; Husby S; Grønbæk K; Jerkeman M; Laurell A; Räty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundström C; Ehinger M; Karjalainen-Lindsberg ML; Delabie J; Ralfkiær E; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH;
Biol Blood Marrow Transplant; 2017 Mar; 23(3):428-435. PubMed ID: 28039078
[TBL] [Abstract][Full Text] [Related]
5. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.
Munshi NC; Avet-Loiseau H; Anderson KC; Neri P; Paiva B; Samur M; Dimopoulos M; Kulakova M; Lam A; Hashim M; He J; Heeg B; Ukropec J; Vermeulen J; Cote S; Bahlis N
Blood Adv; 2020 Dec; 4(23):5988-5999. PubMed ID: 33284948
[TBL] [Abstract][Full Text] [Related]
6. [Minimal residual disease in adults with Philadelphia chromosome negative acute lymphoblastic leukemia in high-risk].
Li ZR; Zhao T; Liu YR; Wang YZ; Xu LP; Zhang XH; Wang Y; Jiang H; Chen YY; Chen H; Han W; Yan CH; Wang J; Jia JS; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):554-560. PubMed ID: 32397017
[No Abstract] [Full Text] [Related]
7. Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis.
Berry DA; Zhou S; Higley H; Mukundan L; Fu S; Reaman GH; Wood BL; Kelloff GJ; Jessup JM; Radich JP
JAMA Oncol; 2017 Jul; 3(7):e170580. PubMed ID: 28494052
[TBL] [Abstract][Full Text] [Related]
8. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277
[TBL] [Abstract][Full Text] [Related]
9. [The prognostic significance of dynamic monitoring of minimal residual disease (MRD) status in patients with newly-diagnosed multiple myeloma].
Yang PY; Liu MM; Fan HQ; Yang YP; Han W; Yu XY; Yue TT; Su KJ; Guo Q; Gao SJ; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):584-588. PubMed ID: 32397022
[No Abstract] [Full Text] [Related]
10. Minimal Residual Disease and Survival Outcomes in Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis.
Molica S; Giannarelli D; Montserrat E
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):423-430. PubMed ID: 31027992
[TBL] [Abstract][Full Text] [Related]
11. Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance.
Klener P; Fronkova E; Kalinova M; Belada D; Forsterova K; Pytlik R; Blahovcova P; Simkovic M; Salek D; Mocikova H; Prochazka V; Janikova A; Vaskova M; Mejstrikova E; Kodet R; Trka J; Trneny M
Hematol Oncol; 2018 Dec; 36(5):773-778. PubMed ID: 30129045
[TBL] [Abstract][Full Text] [Related]
12. Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.
Short NJ; Zhou S; Fu C; Berry DA; Walter RB; Freeman SD; Hourigan CS; Huang X; Nogueras Gonzalez G; Hwang H; Qi X; Kantarjian H; Ravandi F
JAMA Oncol; 2020 Dec; 6(12):1890-1899. PubMed ID: 33030517
[TBL] [Abstract][Full Text] [Related]
13. Post-induction Measurable Residual Disease Using Multicolor Flow Cytometry Is Strongly Predictive of Inferior Clinical Outcome in the Real-Life Management of Childhood T-Cell Acute Lymphoblastic Leukemia: A Study of 256 Patients.
Tembhare PR; Narula G; Khanka T; Ghogale S; Chatterjee G; Patkar NV; Prasad M; Badrinath Y; Deshpande N; Gudapati P; Verma S; Sanyal M; Kunjachan F; Mangang G; Gujral S; Banavali S; Subramanian PG
Front Oncol; 2020; 10():577. PubMed ID: 32391267
[No Abstract] [Full Text] [Related]
14. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma.
Pott C; Schrader C; Gesk S; Harder L; Tiemann M; Raff T; Brüggemann M; Ritgen M; Gahn B; Unterhalt M; Dreyling M; Hiddemann W; Siebert R; Dreger P; Kneba M
Blood; 2006 Mar; 107(6):2271-8. PubMed ID: 16332971
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease in systemic light chain amyloidosis: a systematic review and meta-analysis.
Li X; Yu Y; Yu H; Chen M; Zhang X; Wu Y
J Cancer Res Clin Oncol; 2024 Apr; 150(4):193. PubMed ID: 38619663
[TBL] [Abstract][Full Text] [Related]
16. Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study.
Torka P; Akhtar OS; Reddy NM; Baysal BE; Kader A; Groman A; Nichols J; Mavis C; Tario JD; Block AW; Sait SNJ; Ghione P; Sundaram S; Przespolewski ER; Mohr A; Lund I; Kostrewa J; McWhite K; DeMarco J; Johnson M; Darrall A; Thomas-Talley RN; Wallace PK; Neppalli V; Hutson A; Hernandez-Ilizaliturri FJ
Cancer; 2022 Apr; 128(8):1595-1604. PubMed ID: 35157306
[TBL] [Abstract][Full Text] [Related]
17. [Role of minimal residual disease detection by multiparameter flow cytometry in newly diagnosed multiple myeloma: an analysis of 106 patients].
Deng SH; Xu Y; Sui WW; Wang HJ; Li ZJ; Wang TY; Liu W; Huang WY; Lyu R; Li J; Fu MW; Zou DH; An G; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):376-381. PubMed ID: 29779345
[No Abstract] [Full Text] [Related]
18. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.
Pott C; Hoster E; Delfau-Larue MH; Beldjord K; Böttcher S; Asnafi V; Plonquet A; Siebert R; Callet-Bauchu E; Andersen N; van Dongen JJ; Klapper W; Berger F; Ribrag V; van Hoof AL; Trneny M; Walewski J; Dreger P; Unterhalt M; Hiddemann W; Kneba M; Kluin-Nelemans HC; Hermine O; Macintyre E; Dreyling M
Blood; 2010 Apr; 115(16):3215-23. PubMed ID: 20032498
[TBL] [Abstract][Full Text] [Related]
19. Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis.
Li H; Li F; Zhou X; Mei J; Song P; An Z; Zhao Q; Guo X; Wang X; Zhai Y
Ann Hematol; 2019 May; 98(5):1185-1195. PubMed ID: 30721336
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic significance of early assessment of minimal residual disease in acute myeloid leukemia with mutated NPM1 patients].
Zhao T; Zhu HH; Wang J; Jia JS; Yang SM; Jiang H; Lu J; Chen H; Xu LP; Zhang XH; Jiang B; Ruan GR; Wang DB; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2017 Jan; 38(1):10-16. PubMed ID: 28219218
[No Abstract] [Full Text] [Related]
[Next] [New Search]